University of Edinburgh Centre for Inflammation Research, Institute for Regeneration and Repair, Queen's Medical Research Institute, Edinburgh bioQuarter, 47 Little France Crescent, Edinburgh EH16 4TJ, U.K.
Clin Sci (Lond). 2022 Feb 11;136(3):197-222. doi: 10.1042/CS20201474.
Tumorigenesis is a highly complex process, involving many interrelated and cross-acting signalling pathways. One such pathway that has garnered much attention in the field of cancer research over the last decade is the Hippo signalling pathway. Consisting of two antagonistic modules, the pathway plays an integral role in both tumour suppressive and oncogenic processes, generally via regulation of a diverse set of genes involved in a range of biological functions. This review discusses the history of the pathway within the context of cancer and explores some of the most recent discoveries as to how this critical transducer of cellular signalling can influence cancer progression. A special focus is on the various recent efforts to therapeutically target the key effectors of the pathway in both preclinical and clinical settings.
肿瘤发生是一个高度复杂的过程，涉及许多相互关联和交叉作用的信号通路。在过去十年的癌症研究领域中，Hippo 信号通路就是这样一条备受关注的通路。该通路由两个拮抗模块组成，在肿瘤抑制和致癌过程中都发挥着重要作用，通常通过调节一系列涉及多种生物学功能的基因来实现。本文综述了该通路在癌症中的历史，并探讨了最近关于这种细胞信号转导关键调节剂如何影响癌症进展的一些发现。特别关注的是在临床前和临床环境中，针对该通路关键效应物的各种最近的治疗靶向努力。
